Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.

ABSTRACT:

Background

Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement.

Methods

Paraffin-embedded tumour samples of women with high-risk EC (HR-EC) from the PORTEC-3 trial (n = 424), and a Dutch prospective clinical cohort called MST (n = 256), were used. All cases were molecularly classified. Expression of L1CAM, ER and PR were analysed by whole-slide immunohistochemistry and CTNNB1 mutations were assessed with a next-generation sequencing. Kaplan-Meier method, log-rank tests and Cox's proportional hazard models were used for survival analysis.

Results

In total, 648 HR-EC were included. No independent

SUBMITTER: Vermij L 

PROVIDER: S-EPMC10050005 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature